PHASE I STUDY TO EVALUATE THE SAFETY OF CELLULAR ADOPTIVE IMMUNOTHERAPY, CD4+

评估细胞过继免疫疗法 CD4 安全性的 I 期研究

• 批准号: 7603444
• 负责人: Cassian Yee
• 金额: $ 0.24万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603444
• 关键词: Adoptive Immunotherapy; Antigen Targeting; CD4 Positive T Lymphocytes; Cell Survival; Computer Retrieval of Information on Scientific Projects Database; Dose; Funding; Grant; Growth Factor; Infusion procedures; Institution; Melanoma Cell; Outcome Measure; Phase; Research; Research Personnel; Resources; Safety; Source; T-Lymphocyte; Toxic effect; United States National Institutes of Health; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The safety, survival and anti-tumor effect of infusions of CD4+ T cells are evaluated in this study. CD4 + T cells produce their own growth factors and may survive for prolonged periods after infusion. This is a dose escalation study in which increasing doses of CD4 T cells targeting an antigen found on melanoma cells are given at three different levels. Outcome measures for this study include toxicity, T cell survival after infusion, tumor shrinkage and loss of targeted antigen expression by the tumor after T cell infusion.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究评价了输注CD 4 + T细胞的安全性、存活率和抗肿瘤作用。CD 4 + T细胞产生它们自己的生长因子，并且可以在输注后存活很长时间。这是一项剂量递增研究，其中以三种不同水平给予靶向黑素瘤细胞上发现的抗原的CD 4 T细胞的递增剂量。 本研究的结果指标包括毒性、输注后T细胞存活、肿瘤缩小和T细胞输注后肿瘤靶向抗原表达的丧失。